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Cerebral ischemia entails rapid tissue damage in the af-
fected brain area causing devastating neurological dys-
function. How each component of the neurovascular unit
contributes or responds to the ischemic insult in the con-
text of the human brain has not been solved yet. Thus, the
analysis of the proteome is a straightforward approach to
unraveling these cell proteotypes. In this study, post-mor-
tem brain slices from ischemic stroke patients were ob-
tained corresponding to infarcted (IC) and contralateral
(CL) areas. By means of laser microdissection, neurons
and blood brain barrier structures (BBB) were isolated
and analyzed using label-free quantification. MS data
are available via ProteomeXchange with identifier
PXD003519. Ninety proteins were identified only in neu-
rons, 260 proteins only in the BBB and 261 proteins in both
cell types. Bioinformatics analyses revealed that repair
processes, mainly related to synaptic plasticity, are out-
lined in microdissected neurons, with nonexclusive im-
portant functions found in the BBB. A total of 30 proteins
showing p< 0.05 and fold-change> 2 between IC and CL
areas were considered meaningful in this study: 13 in
neurons, 14 in the BBB and 3 in both cell types. Twelve of
these proteins were selected as candidates and analyzed
by immunohistofluorescence in independent brains. The
MS findings were completely verified for neuronal SAHH2
and SRSF1 whereas the presence in both cell types of
GABT and EAA2 was only validated in neurons. In addi-
tion, SAHH2 showed its potential as a prognostic bio-
marker of neurological improvement when analyzed
early in the plasma of ischemic stroke patients. There-
fore, the quantitative proteomes of neurons and the BBB
(or proteotypes) after human brain ischemia presented
here contribute to increasing the knowledge regarding
the molecular mechanisms of ischemic stroke pathol-
ogy and highlight new proteins that might represent
putative biomarkers of brain ischemia or therapeutic
targets. Molecular & Cellular Proteomics 17: 10.1074/
mcp.RA117.000419, 175–189, 2018.
Stroke is currently a leading cause of death and disability
worldwide. Ischemic stroke represents 85% of all stroke
cases and is characterized by the impairment of blood flow to
a specific region of the brain parenchyma caused by the
occlusion of a cerebral artery (1). During ischemia, a complex
cascade of events is triggered by the lack of oxygen and
nutrient supply. This process includes an increase in excito-
toxicty and oxidative stress, an exacerbated inflammatory
response and the disruption of the blood-brain barrier (BBB)1.
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Finally, rapid cell death and tissue injury lead to a loss of
neurological function (2).
Prompter and more accurate diagnosis of stroke relies
mainly on neuroimaging and is essential for prescribing the
most adequate primary treatment, currently based on reper-
fusion strategies (3, 4). Although effective, these therapies are
given to a small number of ischemic stroke patients, because
of their narrow therapeutic window and some contraindica-
tions. Besides, and unfortunately, neuroprotective therapies
have systematically failed when tried in a real clinical setting
(5); thus, new therapeutic targets are still needed for stroke
patients. In relation to diagnosis, despite their relatively wide
availability, neuroimaging devices are not easily accessible in
certain scenarios such as primary healthcare centers, pre-
hospital settings or developing countries. The use of molec-
ular biomarkers to rapidly distinguish ischemic stroke from
other neurological disorders represents a plausible and af-
fordable tool, especially in those situations (6, 7). Besides,
stroke biomarkers have also shown evidence of their potential
usefulness at other management stages of stroke patients
such as the evaluation of poststroke prognosis and compli-
cations (8, 9).
During recent years, the identification of multiple proteins
related to the mechanisms underlying brain ischemia has
been boosted by the development of new proteomic ap-
proaches (10). Most of these approaches are based on the
examination of body fluids such as serum, plasma or cere-
brospinal fluid. However, the exploration of protein dynamic
changes directly in the injured tissue might aid in unraveling
new pathophysiological processes allowing the discovery of
potential therapeutic targets and new putative biomarkers
after the translation of these alterations from tissue to biolog-
ical fluids (11–13). Following this reasoning, cerebral tissue
homogenates have been examined in the context of ischemia
in human samples (14, 15) and in stroke experimental models
(16, 17). However, when tissue homogenates are analyzed
only global changes in the protein expression profile can be
identified and the alterations in protein expression at a par-
ticular cellular level are not considered. Following a cell iso-
lation approach based on laser microdissection (LMD), our
group previously described ischemia-related changes in ma-
trix metalloproteinase (18) and in chemokine (19) expression
profiles in neurons and vascular cells dissected from human
brain parenchyma.
The main aim of the present study was to define the quan-
titative proteome of different components of the neurovascu-
lar unit after ischemic stroke (or the proteotypes of brain cell
types after ischemia), following an approach that couples
LMD and label-free MS quantification. As a secondary objec-
tive, we tested the performance of validated proteins for use
as diagnostic or prognostic blood biomarkers for stroke.
EXPERIMENTAL PROCEDURES
Experimental Design and Statistical Rationale—This study was di-
vided into two main parts: a first discovery and validation experiment
in human brain samples and a second pilot exploration of some brain
biomarker candidates in blood samples from stroke patients. Details
about demographics, sample size and the internal controls consid-
ered in each experiment are given below together with a complete
explanation regarding the statistical analyses performed in each step.
Individuals and Sample Collection—
Human Brain Tissue Samples—Twelve patients who died because
of an ischemic stroke were included in this study, based on the
availability of specimens in our brain tissue collection. Briefly, post-
mortem tissue samples from the infarct core (IC) and the contralateral
(CL) areas were collected within the first hours after death by an
experienced neuropathologist supported by computed tomography
imaging. Similar specimens of 2 cm2, 1 cm thick were preserved
either immediately by snap freezing in liquid nitrogen or fixed for 24 h
with 4% paraformaldehyde (PFA) at 4 °C followed by 24 h sucrose
dehydration at 4 °C; afterward, in both cases samples were stored at
80 °C until use. Brain tissue from the IC and CL areas was also
collected after being fixed into 10% buffered formalin for 3 weeks and
embedded in paraffin blocks. Table I shows the demographic and
clinical data of the patients as well as the phase of the study in which
each sample was employed.
Blood Samples—All included patients were consecutively admitted
into the emergency department of the Vall d’Hebron University Hos-
pital (Barcelona, Spain) from December 2013 to August 2014 within
the first 6 h after neurological symptoms onset and with stroke
suspicion. On admission, all patients underwent a standardized pro-
tocol of brain imaging for the differential diagnosis of ischemic stroke
or stroke-mimicking conditions. Trained neurologists performed a
neurological severity assessment by means of the National Institutes
of Health Stroke Scale (NIHSS), functional state assigned using the
modified Rankin scale (mRS) and etiological classification following
the TOAST definitions (20) and demographic and clinical data were
also obtained. When eligible, ischemic stroke patients received the
standard thrombolytic treatment [intravenous 0.9 mg/Kg recombinant
tissue-plasminogen activator (rt-PA)] and/or mechanical thrombec-
tomy to remove the arterial clot.
Peripheral blood samples were drawn on admission and always
before any treatment was administered. EDTA plasma and serum
were separated by centrifugation at 1500  g for 15 min at 4 °C and
aliquots were stored at 80 °C until use. From this codified blood
collection, and based on sample availability, 45 ischemic stroke pa-
tients and 13 patients with stroke-mimicking conditions were retro-
spectively selected. Additionally, 8 subjects free of brain lesions from
the ISSYS cohort (21) were also included as controls.
Ethics Statement—The ethical committee of Vall d’Hebron Hospi-
tal approved all studies (brain - PR[HG]85/2004 - and blood -
PR[AG]157/2011 and PR[IR]87/2010 - sampling) and written informed
consent was obtained from all subjects or relatives in accordance
with the Declaration of Helsinki.
in hYpertensiveS; LMD, laser microdissection; LTQ, linear trap qua-
drupole; mRS, modified Rankin Scale; mTOR1, mammalian target of
Rapamycin 1; NeuN, neuronal nuclei; NIHSS, National Institutes of
Health Stroke Scale; ORadj, adjusted odds ratio; PADI2, protein-
arginine deiminase type-2; PFA, paraformaldehyde; RASK, GTPase
KRas; ROC, receiver operator characteristic; rt-PA, recombinant
tissue-plasminogen activator; SAHH2, adenosylhomocysteinase 2;
SD, standard deviation; SRPK, serine/arginine-rich protein kinase;
SRSF1, serine/arginine-rich splicing factor 1; TCEP, tris (2-carboxy-
ethyl) phosphine; TEAB, triethylammonium bicarbonate; TOAST, Trial
of Org 10172 in acute stroke treatment; TPBS, Tween-PBS; TTBS,
Tween-TBS; UEA-I, Ulex europaeus agglutinin I.
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Laser Microdissection (LMD)—Henceforth, all materials were pur-
chased from Sigma-Aldrich (Saint Louis, MO) unless the contrary is
stated.
Snap frozen brain samples were embedded in Tissue-Tek OCT
(Sakura Finetek, Torrance, CA) to be cut into 10 m-thick sections
using a HM505E cryostat (Microm International GmbH, Walldorf, Ger-
many). Sections were mounted onto ultraviolet-irradiated 2 m pol-
yethylene naphthalate membrane slides (MicroDissect GmbH, Her-
born, Germany) and stored at 80 °C for less than 1 week with silica
desiccant pads.
Rapid fluorescence detection of brain structures was performed
following the procedure previously described (18). Neurons were
immunostained using a mouse anti-neuronal nuclei antibody (NeuN,
1:50; cat.#: MAB377, Millipore, Burlington, MA) and a secondary
anti-mouse antibody (AlexaFluor®568, 1:50; cat.#: A11004, Invitro-
gen, Carlsbad, CA) whereas endothelial cells from brain microvessels
were stained using a FITC conjugated Ulex europaeus agglutinin I
(UEA-I, 1:20; cat.#: L9006). Immediately after staining, LMD was
performed on individual cells, either neuronal bodies or BBB struc-
tures. The term “BBB structures” is used instead of “endothelial cells”
because astrocytes’ end-feet and pericytes are closely related to
endothelial cells and as a result brain microvasculature cannot be
completely isolated (22, 23). The 20 objective of a LMD6000 micro-
scope (Leica Microsystem, Wetzlar, Germany) was used to dissect
the cells in a contact-free manner into dry 0.65 ml tube caps (Soren-
son BioScience, Murray, UT) at a power of 45 KW, an aperture of 11
and a speed of 14 ns for a maximum of 4.5 h. Approximate total areas
of 106 m2 for neurons (2500 cells) and BBB (4000 units) were
collected from both IC and CL areas in 60 l of 0.1% Rapigest
surfactant (Waters, Milford, MA) in 0.1 M triethylammonium bicarbon-
ate (TEAB). Samples were sonicated on ice at 70% amplitude for
intervals of 10 s for a total of 2 min and stored at 80 °C until use. An
equivalent area of polyethylene naphthalate membrane pieces with-
out brain tissue was also dissected as a negative control.
Proteomics Analysis—
Sample Preparation—A total of 30 l of each sample enriched in
human neurons or BBB structures were reduced with 2 l freshly
prepared 50 mM Tris(2-carboxyethyl)phosphine (TCEP) for 1 h at
60 °C, alkylated with 1 l freshly prepared 400 mM iodoacetamide
(IAA) for 30 min at room temperature under agitation in the dark, and
finally digested with 2 l 0.05 g/l trypsin (Promega, Madison, WI) in
0.1 M TEAB overnight at 37 °C. Afterward, Rapigest was removed
from the preparation by precipitation with 20 l 3.5% TFA for 1 h at
37 °C. The same process was followed for LMD negative control
samples. All samples were centrifuged for 20 min at 13,000  g and
supernatants were dried under vacuum. Samples were solubilized in
300 l 5% ACN 0.1% formic acid (FA), purified using microspin C18
columns (Harvard Apparatus, Cambridge, MA) according to the ma-
nufacturer’s instructions and dried again under vacuum. Lyophilized
samples were solubilized in 20 l 5% ACN 0.1% FA, centrifuged for
5 min at 14,000 g, transferred to a sample vial and frozen at20 °C
until use.
LC-MS/MS Analysis—LMD samples were analyzed by LC-ESI-
MS/MS on a linear trap quadrupole (LTQ) Orbitrap Velos Pro (Thermo
Fisher Scientific, Waltham, MA) equipped with a NanoAcquity UPLC
system (Waters). A total of 4 injections (4 l each) per sample were
performed. Peptides were trapped on a home-made 5 m 200 Å
Magic C18 AQ 0.1  20 mm pre-column (Unichrom Scientific, Taipei
city, PR China) and separated on a commercial 0.075 150 mm 5 m
100 Å C18 analytical nanocolumn (Nikkyo Technos Co., Ltd, Tokyo,
Japan). The analytical separation was performed using a gradient of
H2O/FA 99.9%/0.1% (solvent A) and ACN/FA 99.9%/0.1% (solvent B)
as follows: 0–1 min 95% A and 5% B, then to 65% A and 35% B in
54 min, then to 20% A and 80% B in 10 min, then stay 2 min at 20%
A and 80% B, then back to 95% A and 5% B in 2 min and finally
re-equilibrate at 95% A and 5% B for 16 min. The flow rate was
always of 220 nL/min for a total run time of 85 min.
For MS survey scans, the Orbitrap resolution was set to 60,000 and
the ion population was set to 5  105. Up to five precursor ions were
selected for CID in the LTQ. The ion population was set to 104 with an
isolation width of 2 m/z. The normalized collision energies were set to
35% for CID. Gas phase fractionation (GPF) (24) was performed using
four mass ranges for data-dependent MS/MS selection. The GPF
ranges were the following: 400–520 m/z; 515–690 m/z; 685–979 m/z
and 974–2000 m/z.
Complete MS raw data have been uploaded to the Proteome-
Xchange Consortium through the PRIDE repository (25) with data
identifiers PXD003519 and 10.6019/PXD003519. Furthermore, pro-
tein and peptide identifications in both neurons and the BBB are
provided as supplemental Data S1.
Protein Quantification and Identification—Progenesis® QI for pro-
teomics software v3.0 (Nonlinear dynamics, Newcastle upon Tyne,
UK) was used for MS data analysis using default settings. In this
study, neuron and BBB samples were considered as independent
experiments and were analyzed separately. Each GPF range was
analyzed independently and all MS runs were automatically aligned to
an automatically selected reference sample with manual supervision
and they were automatically normalized to all features. Only noncon-
TABLE I
Demographic and clinical data from patients included in the brain tissue study. Brain samples were obtained from both infarcted core (IC) and
healthy contralateral (CL) areas. rt-PA: recombinant tissue-plasminogen activator; T-O-D: time from onset of stroke symptoms to death; PMI:
postmortem interval (from death to brain samples collection); BBB: blood-brain barrier structures; IHF: immunohistofluorescence
Patient
number Sex
Age
(years)
Lesion location
(hemisphere)
rt-PA
treatment
T-O-D
(h)
PMI
(h)
Necropsy
collection
(year)
Included in
MS analysis Included in
IHF analysis
Neurons BBB
N 12 Female 77 Left Yes 72 4 2005 X
N 15 Male 72 Right No 13 3 2005 X
N 16 Female 79 Left No 88 5 2005 X X
N 19 Female 50 Left Yes 120 9 2006 X
N 22 Male 67 Left Yes 62 7 2007 X
N 24 Female 83 Left Yes 100 14.5 2007 X
N 29 Female 92 Right No 67 25 2007 X
N 32 Male 73 Left No 360 6 2008 X
N 33 Male 80 Right No 100 4.5 2009 X X
N 35 Male 84 Left No 40 8 2009 X X
N 36 Female 73 Left Yes 44 4 2010 X X
N 38 Male 75 Left Yes 19 5 2011 X
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flicting features within the 400 to 1500 m/z range, 20 to 80 min
retention time and with positive charges between 2 to 7 were con-
sidered for identification and quantification. Peak lists were generated
by Progenesis and analyzed using the Mascot search engine (v2.2,
Matrix Science, London, UK). Protein identification was carried out
using the SwissProt-human database (2017_01: 20,171 entries), set-
ting precursor mass tolerance to 10 ppm and fragment mass toler-
ance to 0.6 Da. Oxidized methionine was considered as variable
amino acid modification and carbamidomethylation of cysteines as
fixed modification. Trypsin was selected as the enzyme allowing up to
one missed cleavage. Significant threshold for protein identification
was set to p  0.05 for the probability-based Mascot score and at
least 2 spectra per peptide.
Finally, the four GPF fractions were combined into one single
Progenesis experiment. Label-free protein abundance quantification
was based on the sum of the peak areas within the isotope bound-
aries of peptide ion peaks. To allow comparison across different
sample runs, the abundance of each protein was normalized to all
proteins. All proteins showed a coefficient of variation (CV) in their
abundance higher than 20% across biological replicates (i.e. IC and
CL all together for each protein). Thus, all proteins were analyzed with
a paired parametric statistical test, comparing IC and CL areas in both
neuron and BBB experiments. Only those proteins quantified and
identified with at least 2 unique peptides, a p value 0.05 and a
fold-change  2 were considered meaningful for further analyses.
Fold-change was calculated by dividing the highest mean normalized
protein abundance by the lowest mean normalized protein abun-
dance. We added a minus sign (-) when the highest abundance was
found in CL area to indicate that protein levels were lower in the IC
area. Furthermore, false discovery rate (FDR) using the Benjamini-
Hochberg procedure was calculated accounting all proteins identified
with at least 2 unique peptides, for each dataset (R software (3.3.2, R
development core team 2012; Austria), multtest R package).
Bioinformatics Analysis—Proteins identified with at least 2 unique
peptides in neurons and BBB experiments were analyzed separately
through core analyses using Qiagen’s Ingenuity® Pathway Analysis
(IPA, Qiagen, Hilden, Germany). Default settings were used but dif-
ferent background IPA Knowledge Bases were selected for each cell
type. IPA contents of the central nervous system and neurons were
selected in the case of neurons, whereas central nervous system,
endothelial cells, astrocytes and vascular smooth muscle cells were
exclusively selected for BBB analysis. In both cases, a filter of p value
0.05 and fold-change  2 for the IC versus CL comparison was
applied to highlight key proteins through the IPA outputs. Protein
identifiers were mapped into the IPA Knowledge Base to identify
connectivity networks, biological functions and canonical pathways in
which foremost proteins in neurons and/or the BBB are relevant in
stroke setting. To that end, overlap p values were calculated by
right-tailed Fisher’s exact test, adjusted by Benjamini-Hochberg mul-
tiple testing correction and considered significant at an adjusted p
value 0.05 (likewise -log(p value)1.3). Moreover, z-scores to pre-
dict activation or inhibition of a network, pathway, or upstream reg-
ulator were calculated based on the overlap between uploaded da-
tasets and IPA Knowledge Base; a cut-off of unbiased z-score  2
was applied to consider this prediction significant. Afterward, both
analyses (neurons and BBB) were compared side-by-side.
Immunohistofluorescence—After the proteomics analysis, protein
candidates were chosen to be verified by means of immunohistofluo-
rescence analysis of brain tissue samples obtained from new patients
(Table I). Candidate selection was performed based on MS data
statistical analysis results and on the availability of commercial
antibodies.
Depending on the validated antibody application, samples fixed
into PFA (12 m cryosections) or paraffin-embedded (3 m sections)
were used within one month after cutting. PFA samples were fixed in
cold-acetone for 15 min before washing in 0.1% Tween-PBS (TPBS;
Gibco, Gaithersburg, MD) for 5 min while a standard deparaffinization
protocol was performed in paraffin-embedded samples, with a final
wash in 0.1% Tween-TBS (TTBS).
Antigen retrieval using a citrate buffer (pH 6, 95 °C) for 20 min was
performed in all paraffin-embedded samples and in some PFA-fixed
samples according to antibody manufacturer instructions. Thereafter
samples were blocked with 1% BSA, 5–10% goat serum (Millipore) in
TPBS/TTBS. Slides were then incubated overnight at 4 °C with rabbit
primary antibodies diluted in blocking buffer against adenosylhomo-
cysteinase-2 (SAHH2 or AHCYL1, cat.#: ab178693, Abcam, Cam-
bridge, UK), serine/arginine-rich splicing factor-1 (SRSF1 or SF2,
cat.#: ab129108, Abcam), excitatory amino acid transporter-2 (EAA2
or GLT1, cat.#: NBP1–59632, Novus Biologicals, Littleton, CO),
GTPase KRas (RASK or KRAS, cat.#: H00003845-M01, Novus; also
cat.#: A1190, Neo Scientific, Woburn, MA), hepatocyte cell adhesion
molecule (HECAM or HepaCAM, cat.#: sc-168078, Santa Cruz Bio-
technology Inc., Dallas, TX), serrate RNA effector molecule homolog
(SRRT or ARS2, cat.#: H00051593-B02P, Novus), protein-arginine
deiminase type-2 (PADI2, cat.#: ab16478 and also ab50257, Abcam),
cytochrome b-c1 complex subunit 7 (QCR7 or UQCRB, cat.#:
ab190360, Abcam), NAD-dependent protein deacetylase sirtuin-1
(SIR2 or SIRT2, cat.#: H00022933-M01, Novus; also cat.#: A0273,
Neo), neurotrimin (NTRI, cat.#: sc-390941, Santa Cruz), endophi-
lin-A1 (SH3G2 or SH3GL2, cat.#: ab55702 and also ab169762,
Abcam), and mitochondrial 4-aminobutyrate aminotransferase (GABT
or ABAT, cat.#: ab81432, Abcam). Mouse anti-NeuN and TRITC con-
jugated UEA-I lectin (cat.#: L4889) were used as neuron and BBB
markers, respectively. AlexaFluor® 488 anti-rabbit IgG (cat.#:
A11008, Life Technologies, Carlsbad, CA) and AlexaFluor® 568 anti-
mouse IgG were used as secondary antibodies diluted in blocking
buffer. After washing, Sudan Black B staining was performed to
reduce brain tissue autofluorescence (26) and sections were mounted
on coverslips using Vectashield with 46-diamidino-2-phenyl indole
(DAPI; Vector laboratories, Burlingame, CA). Negative controls were
performed in each case without the primary antibody for selected
protein candidates.
Tissue slides were analyzed using an FV-1000 laser confocal spec-
tral microscope (Olympus, Tokyo, Japan) with the same intensities
and parameters for all slides being qualitatively compared and for all
samples for a given protein candidate. Images were processed with
Fluoview v1.7a (Olympus).
Blood Biomarker Pilot Exploration—
ELISA—Those proteins whose expression showed a similar cell
localization pattern by immunofluorescence in human brain samples
as in MS were explored as blood stroke biomarkers in a first pilot
experiment, using commercially available ELISA kits. Circulating lev-
els of SAHH2 (cat.#: E12635h, EIAab, Wuhan, PR China) and SRSF1
(cat.#: CSB-EL021142HU, Cusabio, College Park, MD) were tested
following manufacturer’s instructions by trained technicians blinded
to clinical details. OD was measured in a SynergyTM Mx microplate
reader (BioTek Instruments Inc., Winooski, VT).
Each sample was assayed twice and the mean value was used.
Samples with a coefficient of variation (CV) between duplicates higher
than 20% were excluded and samples with values under or over the
detectable range of the assay were given the limit of detection value
or the highest readable value, respectively. In each 96-well plate, a
commercial sample pool was assayed in quatriplicates to be used as
inter-assay control (plasma from Innovative Research, Novi, MI, cat.#:
IPLA-N; serum, cat.#: H16914).
Statistical Analyses—
Analyses Were Performed with SPSS 17.0 Software (SPSS Inc,
USA) Unless Stated Otherwise—In the case of SRSF1, the inter-assay
Microdissected Stroke Brain and Label-free Proteomics
178 Molecular & Cellular Proteomics 17.1
CV was higher than 20% and thus values were standardized prior to
statistical analysis by calculating the Z-score value for each assay kit
(in which different patient groups were equally distributed), by sub-
tracting the mean and dividing by the standard deviation (S.D.) and
adding two units to avoid negative results to each sample.
The primary endpoints to be analyzed were (1) differential diagnosis
of stroke when compared with stroke-mimicking conditions and con-
trols, and (2) early neurological outcome prediction in ischemic stroke
patients, with neurological improvement/worsening defined as a de-
crease/increase in the NIHSS score by 4 or more points at 24 h or 48 h
from admission (27).
The Kolmogorov-Smirnov test was used to assess normal distri-
bution of the data (p  0.05); as nonnormal distribution was found
Kruskal-Wallis or Mann-Whitney U tests or Spearman’s correlation
were applied. For clinical variables, ordinal ones were analyzed as
nonnormal distributed variables and the median and interquartile
range (IQR) were shown, whereas continuous variables were analyzed
by Student’s t test and mean and S.D. values were given. Categorical
variables were assessed by Pearson chi-squared test and are ex-
pressed as frequencies.
Cut-off points for biomarkers associated with an end point were
obtained from their receiver operator characteristic (ROC) curve to
discriminate early neurological improvement with the optimal accu-
racy (both sensitivity and specificity). To assess the independent
association of biomarkers, a multivariate logistic regression model
was built by the forward stepwise method with clinical variables
associated with the end point at p value0.1. Subsequently, dichot-
omized values of biomarkers were added to the clinical regression
model by the enter method. Odds ratios adjusted by age and sex
(ORadj) and 95% confidence interval are given. Finally, the discrimi-
native potential of both predictive models was compared by De-
Long’s method using the areas under the ROC curve (AUC) of only
clinical or clinical biomarkers models (pROC R package). Moreover,
the integrated discrimination improvement (IDI) index was calculated
to assess the added value of biomarkers to the clinical predictive
model (Hmisc R package).
In all cases, a p value 0.05 was considered significant at a 95%
confidence level.
RESULTS
A summarized workflow chart of the whole study is shown
in Fig. 1A.
LMD-Proteomics—The specific changes that occur under
ischemia in neurons and BBB structures were determined
from the differential protein profile obtained between IC and
CL areas of these microdissected cell types. A total of 43.3%
of the quantified proteins were identified with at least 2 unique
peptides: 365 proteins were identified in neurons and 539
FIG. 1. Study schematic description. A, Workflow chart of the different stages of our study. B, Volcano plots of the neurons and BBB
datasets after MS analysis. Highlighted in black those proteins with a p value 0.05 (-log10(p) 1.3) and a fold-change 2 (log2(FC) 1) when
IC and CL areas were compared. IC: infarct core; CL: contralateral area; FC: fold-change; BBB: blood brain barrier structures; LTQ: linear trap
quadrupole.
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proteins were identified in the BBB (supplemental Table S1).
After statistical analysis of the MS data comparing both brain
areas, the FDR for those proteins showing a p value 0.05
was 27% in the neurons and 69% in the BBB. To focus on the
most biologically meaningful changes in the IC brain area, a p
value 0.05 and a fold-change 2 were applied to highlight
the candidate proteins in each dataset: 55 proteins in neurons
and 23 proteins in BBB (Fig. 1B).
Bioinformatics Analysis—The proteotypes of neurons and
the BBB revealed some common but also diverse information
about the biological processes and molecular functions taking
place under brain ischemia in these two main structures.
Clearly, the citric acid cycle (-log(B-H p value)  9.87) and
mitochondrial function (-log(B-H p value)  2.67) were partic-
ularly altered in the microdissected neurons whereas any
relevant canonical pathway showed up as exclusive to the
BBB (Fig. 2A). Cell assembly, organization, and interaction
together with cell death appeared as the foremost altered
biological functions in both neurons and BBB proteotypes
(Fig. 2B). In-depth analysis showed changes in cell assembly
and interaction processes as being consistent for the
neuronal dataset, where several IC-up-regulated proteins
were revealed as regulators of plasticity processes (including
up-regulation of neuritogenesis, elongation of axons and su-
pression of synaptic depression) (Fig. 3A). Furthermore, cell
death in the cerebral cortex was the top function predicted to
be activated in both neurons and the BBB (z-scores of 2 for
neurons and of 1.96 for BBB) (Fig. 3B). Interestingly, adeno-
sine receptor A2a (ADORA2A) was predicted as activated
upstream regulator of several IC-up-regulated proteins in neu-
rons (z-scores of 2.05). These up-regulated proteins were
again related to cell organization processes involving produc-
tion of cell energy, cytoskeleton and transport through vesi-
cles (Fig. 3C).
FIG. 2. Representative pathways and functions of each cell proteotype after ischemic stroke. A, Comparative list of canonical
pathways, and B, comparative list of biological functions, in neurons and/or BBB structures. Only those pathways and functions with a
Benjamini-Hochberg corrected p value 0.05 (-log (p value) 1.3) at least in one of the cell types were represented. Dark bar denote neurons
and light bar denote BBB structures.
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Moreover, cell organization, assembly, interaction and
signaling processes were found again to be important in
ischemic neurons as 3 top networks were created with
mostly IC-up-regulated proteins. The top networks for
neurons and BBB proteotypes are shown in supplemental
Fig. S1.
Verification of Candidates—From the lists of proteins mean-
ingfully altered by ischemia in neurons and BBB structures,
FIG. 3. Regulation of proteins after ischemia alters biological functions in neurons and BBB. A, Schema of the cell assembly,
organization and interaction processes occurring in neurons of the infarct core (IC). B, Cell death in the cerebral cortex is activated in both
neurons and BBB structures (in red, proteins found altered in both cell types). C, Upstream regulator predicted to be activated in neurons of
the IC. Geometric red figures represent IC-up-regulated proteins taking part in these biological functions whereas green figures represent
IC-downregulated proteins. Based on the state of the protein and their role in the process (arrow indicating activator, dash indicating inhibitor),
the nature of several biological processes was predicted: orange indicates predicted activation andblue indicates predicted inhibition. Gray
lines indicate direct relationship among proteins. ACTG1: actin, ADORA2A: adenosine receptor A2a, ALDOC: fructose-bisphosphate aldolase
C, AP2A1: AP-2 complex subunit alpha-1, ATP1A3: sodium/potassium-transporting ATPase subunit alpha-3, ATP2B1: plasma membrane
calcium-transporting ATPase 1, CAMKV: CaM kinase-like vesicle-associated protein, CFL1: cofilin-1, CRMP1: Dihydropyrimidinase-related
protein 1, DPYSL2: Dihydropyrimidinase-related protein 2, EAA2: excitatory amino acid transporter 2, FBXO2: F-box only protein 2, GAPDH:
glyceraldehyde-3-phosphate dehydrogenase, GNAO1: guanine nucleotide-binding protein G(o) subunit alpha, GSN: gelsolin, HSPB1: heat
shock protein beta-1, NAPB: beta-soluble NSF attachment protein, PACSIN1: syndapin-1, RAB3A: Ras-related protein Rab-3A, RPS3: 40S
ribosomal protein S3, SEPT11: septin-11, SH3GL2: endophilin-A1, SYN1: synapsin-1.
Microdissected Stroke Brain and Label-free Proteomics
Molecular & Cellular Proteomics 17.1 181
focus was set on those proteins showing a cell-specific re-
sponse to ischemia, i.e. being exclusively identified in one cell
type, and those proteins performing equally under ischemia in
both cell types studied (i.e. global ischemia response). Table
II shows the list of 30 proteins fulfilling these criteria from
where 12 proteins were chosen to be verified by immuno-
histofluorescence in new human brain samples. In our study,
6 out of 12 antibodies showed poor performance and regret-
tably these proteins could not be assessed in this phase of the
study.
For the other candidates, RASK was detected in vessel
structures, in contradiction to our MS findings, and thus it was
not further evaluated. PADI2 was correctly found in the BBB
structures of the IC but inconsistently across different patient
samples. Furthermore, of those candidates found to be al-
tered in both cell types studied, GABT was found raised in
most IC samples but only in the neurons and EAA2 was more
abundant in the neuronal bodies, with an intense signal sur-
rounding the nuclei, than in the BBB but with an unclear
expression pattern throughout IC and CL samples (data not
shown).
As expected, SAHH2 and SRSF1 were both identified in
neurons showing higher expression levels in the IC when
compared with the CL area. Specifically, the SRSF1 signal
was gathered in the neuronal body showing a shift from the
nucleus to the cytoplasm in the IC, whereas SAHH2 was
detected in the neuronal bodies and also in the axons (Figs.
4A and 4B).
Blood Biomarker Exploration—Finally these two completely
verified candidates in the brain tissue were further explored as
diagnostic and prognostic biomarkers for stroke in blood
samples obtained within the first 6 h after symptom onset.
Circulating levels of SAHH2 and SRSF1 were not influenced
by age, sex or any other clinical factor (data not shown) but
they did not show any role as diagnostic biomarkers when
their quantified levels were compared between ischemic
strokes, stroke-mimicking conditions and controls (supple-
mental Table S2).
Those ischemic stroke patients showing a neurological
improvement at 24 h, who had higher blood pressure val-
ues, higher NIHSS scores at admission and were more
frequently treated with rt-PA, had lower circulating levels of
SAHH2 at admission than patients whose condition did not
improve (968.9 versus 1498.9 pg/ml, p  0.031). No differ-
ences were observed for SRSF1 (Table III). Once SAHH2
was dichotomized by a cut-off of 993.23 pg/ml (89% sen-
sitivity, 58% specificity) and introduced in the multivariate
clinical model, low admission circulating levels of this bio-
TABLE II
List of proteins altered in infarcted brain areas found by MS analysis exclusively in neurons, BBB structures or both. Bold proteins were selected
as candidates for replication. FC: fold-change
UNIPROT ID Proteinname
Neurons BBB
Main function
P value FC P value FC
O43865 SAHH2 0.006 10.33 Amino-acid biosynthesis pathway.
P01116 RASK 0.010 9.43 GTPase activity.
P62820 RAB1A 0.014 3.40 GTPase activity.
Q02218 ODO1 0.016 4.01 Tricarboxylic acid cycle enzyme.
Q9BY11 PACN1 0.020 4.49 Reorganization of the cytoskeleton.
Q07955 SRSF1 0.028 4.79 Regulation of alternative splicing.
Q7Z4S6 KI21A 0.028 5.13 Microtubule-binding motor protein.
P15880 RS2 0.028 2.21 Ribosomal protein.
P53597 SUCA 0.028 2.39 Tricarboxylic acid cycle enzyme.
Q9NVA2 SEP11 0.035 4.33 Filament-forming cytoskeletal GTPase.
Q9H936 GHC1 0.036 2.44 Transport of Glutamate across the inner mitochondrial
membrane.
P30086 PEBP1 0.040 66.80 Serine protease inhibitor.
P63261 ACTG 0.045 2.09 Cell motility.
Q9BX26 SYCP2 0.006 2.90 Assembly of synaptonemal complexes.
Q96FC7 PHIPL 0.016 2.63 Development of the central nervous system.
P17677 NEUM 0.023 3.78 Axonal and dendritic filopodia induction.
Q14982 OPCM 0.032 3.11 Binding opioids.
Q9BXP5 SRRT 0.034 3.32 Mediator in RNA-mediated gene silencing by miRNAs.
Q15019 SEPT2 0.035 2.06 Filament-forming cytoskeletal GTPase.
P05129 KPCG 0.043 3.53 Protein kinase.
Q14CZ8 HECAM 0.043 6.29 Regulation of cell motility and cell-matrix interactions.
P14927 QCR7 0.047 2.45 Component of the mitochondrial respiratory chain.
Q9Y2J8 PADI2 0.047 6.74 Deimination of arginine residues of proteins.
Q8TAB3 PCD19 0.049 9.04 Cell adhesion protein.
Q9P121 NTRI 0.049 2.58 Neural cell adhesion molecule.
Q8IXJ6 SIR2 0.049 3.02 Regulation of the cytoskeleton.
P43034 LIS1 0.050 2.01 Activation of actin polymerization in neurons.
Q99962 SH3G2 0.017 3.61 0.026 2.59 Synaptic vesicle endocytosis.
P43004 EAA2 0.044 2.21 0.025 3.68 Transport of Glutamate and Aspartate.
P80404 GABT 0.046 6.89 0.030 9.03 Conversion of GABA to Glutamate and succinate.
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marker showed up as an independent predictor of neuro-
logical improvement at 24 h. Moreover, when SAHH2 was
included together with clinical data into this predictive
model, the discrimination between groups of patients in-
creased, with an AUC up to 0.874 and, globally, the predic-
tion of improvement was significantly increased by 20%
when compared with the clinical model alone (p  0.032)
(Table IV).
Similar results for admission levels of SAHH2 were obtained
for neurological improvement measured at 48 h after stroke
onset (Table IV; supplemental Table S3 shows demographic
and clinical data associated with this end point). At this time
point, rt-PA treatment was the only variable being included in
the clinical regression model. However, this model was not
considered clinically meaningful (i.e. assessing the prognostic
value of the biomarker at admission before deciding whether
rt-PA treatment should be given) and thus a basic model
including NIHSS score was built, as shown in Table IV. None-
theless, dichotomized SAHH2 levels remained as an inde-
pendent predictor even when rt-PA was entered into the
model (data not shown).
Further assessment showed no association between
SAHH2 baseline circulating levels and mortality (15.5%
deaths in this cohort, average time from stroke onset to death
of 6.43 	 4.96 days).
DISCUSSION
Previous studies assessing the changes in the protein ex-
pression profile after human cerebral ischemia were based on
MS analysis of the whole cerebral tissue (14, 15) or explored
the expression of targeted molecules in specific isolated cell
types (18, 19, 28). The study being presented here explored,
for the first time, the proteome of neurons and BBB structures
isolated by LMD from human brains after stroke following a
hypothesis-free analysis based on label-free MS. Moreover,
we applied a GPF approach dividing the m/z range in MS2 to
maximize the protein identification rate when performing a
data dependent acquisition in this type of samples with low
protein amounts (24, 29, 30).
The coupling of LMD and proteomics for the analysis of
specific cell populations has been previously considered in
the context of multiple human brain disorders such as Alzhei-
mer’s (31–33), multiple sclerosis (34) and different types of
tumors (35, 36). In the present study, this type of analysis was
considered especially appropriate to assess proteotypic
changes in ischemic stroke, a pathology in which each com-
ponent of the neurovascular unit presents a different response
to the ischemic insult (2). These different responses were
evidenced in the datasets presented here with sets of proteins
being altered in both isolated cell types as well as neuron-
specific and BBB-specific proteins also being altered.
Pathway-based bioinformatics analysis helped to envision
those processes and functions that are relevant to the patho-
physiology of stroke and those that only affect one cell type.
The alteration of the citric acid cycle and the mitochondrial
function after ischemia exclusively in the neurons might be
related to repair mechanisms, as supported by other high-
lighted biological processes such as synaptic plasticity. The
up-regulation in the IC region of 50% of the enzymes involved
in the citric acid cycle (known to be activated by increased
Ca2 levels (37)) and of some of the proteins belonging to the
electron transport chain indicates an increase in the produc-
tion of cell energy as adenosine triphosphate (ATP). This
energy would be required, among other processes, for neu-
ronal mitochondria remodeling by fission, which under an
ischemic insult is activated by increased Ca2 and free radi-
cals (38). Mitochondrial fission is mainly orchestrated by dy-
namin-related protein 1 (DRP-1 or DNM1L; found up-regu-
lated in our experiment), and this protein is involved in several
biological functions: synaptic plasticity, autophagy (linked to
neuroprotection) and apoptosis (the last step of preventing
brain damage) (reviewed in 39 and 40). ADORA2A was pre-
dicted to be an upstream regulator found in the bioinformatics
analysis. It is one of the two brain adenosine receptors and it
increases intracellular cAMP levels, regulates blood flow and
reduces inflammation and is known to be up-regulated under
hypoxia conditions. It has been related to ischemic brain
FIG. 4. Immunohistofluorescence analyses of human brain
samples. A, SAHH2 (1:400 antibody dilution) is increased in the
neurons of the infarct core (IC) versus contralateral area (CL). B,
SRSF1 (1:100 antibody dilution) was also greater in neurons of IC than
of CL. SAHH2 and SRSF1 signal was detected with green channel
(secondary antibodies at 1:500 dilution), whereas co-localization with
neuronal nuclei immunodetection (NeuN, 1:100 antibody dilution) was
done in red channel. Nuclear detection with DAPI was done in blue
channel. Central images and image inserts showing characteristics
details are representative for each protein immunofluorescence anal-
ysis. Scale bar  50 m. Bar in inserts  10 m.
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damage but also promotes synaptic plasticity (41). Thus, most
of our findings in neurons pointed to brain plasticity processes
being engaged in IC areas and this might be related to the
time from stroke onset to death in the samples available for
this study, with a range around 2 to 15 days after stroke in the
experimental MS analysis.
BBB structures, in contrast to neurons, although undoubt-
edly affected by stroke, did not exhibit consistent exclusive
pathways and functions altered after ischemia. Despite being
surely influenced by the smaller sample size achieved for the
MS analysis and consequently a powerless statistical analy-
sis, these results might be also a direct consequence of a
higher cell complexity in BBB structures, which are near with
other cell types (i.e. astrocytes or pericytes) interfering in their
pure isolation, or of a higher tolerance against the ischemic
insult. It should be noted that only those cells preserving their
morphology and structural integrity could be detected and
isolated by LMD. There was, therefore, no proteomic informa-
tion regarding neurons and BBB structures if they are ex-
tremely disrupted after ischemia.
The top candidates in our datasets were selected to be
validated by immunohistofluorescence in independent tissue
samples. Regrettably, some of the tested antibodies were
found to be inadequate for immunohistochemical applications
and precluded the validation of some interesting candidates.
In other cases, the differential time from onset to death, the
postmortem interval or the tissue preservation method be-
tween the samples used in MS or in the validation assays, or
the heterogeneity of the brain areas hit by stroke, might be
influencing inconsistent findings. In the case of BBB struc-
tures, some false positive candidates were unmasked in the
validation step. Although not completely verified, our find-
ings on EAA2 and GABT still seem relevant for ischemic
stroke.
The brain protein EAA2 (also named SLC1A2 and GLT-1 in
rodents) is responsible for maintaining the glutamate balance
in the synaptic cleft (42). Although EAA2 is mainly an astro-
cytic transporter (42) it has also been detected in other brain
cell types including neurons and endothelial cells (43–45).
Even though the mechanism that regulates the expression of
EAA2 during ischemia is not fully understood, the stimulation
of EAA2 has been shown to prevent neuronal damage after
ischemia. This is probably because of the high glutamate
clearance capability exhibited in the neuroaxis (46, 47). In the
present study, we detected a reduction in EAA2 expression in
both, neurons and BBB isolated from the IC area, thus show-
ing a general response to the ischemic insult. These results
are in line with previous publications that examined EAA2
TABLE III
Univariate analysis: Demographic and clinical characteristics associated with neurological improvement at 24h in ischemic stroke patients.
NIHSS: National Institutes of Health stroke scale; mRS: modified Rankin scale; SBP: systolic blood pressure; DBP: diastolic blood pressure;
SAHH2: adenosylhomocysteinase-2; Z-SRSF1: standardized values for serine/arginine-rich splicing factor-1. Statistically significant differences
between studied groups are highlighted as bold p values and statistical trends are marked with*
Factors
Neurological
improvement (n  13)
No neurological
improvement (n  32)
P value
Age, years median (IQR) 79 (77–82) 81 (68.5–84) 0.539
Sex (Male) % (n) 46.2 (6) 46.9 (15) 0.965
Admission NIHSS score median (IQR) 13 (10–17) 8 (4–16) 0.079*
Previous mRS score median (IQR) 1 (1–1) 1 (0.5–3) 0.851
Glycemia, mg/dL mean 	 S.D. 126.67 	 39.94 138.55 	 39.69 0.384
SBP, mm Hg mean 	 S.D. 159.10 	 20.02 140.32 	 24.91 0.045
DBP, mm Hg mean 	 S.D. 84.90 	 13.30 74.00 	 15.11 0.060*
Smokers % (n) 0 (0) 16.0 (4) 0.303
Arterial hypertension % (n) 76.9 (10) 78.1 (25) 1.000
Diabetes mellitus % (n) 30.8 (4) 25.0 (8) 0.721
Dyslipidemia % (n) 30.8 (4) 46.9 (15) 0.207
Atrial fibrillation % (n) 10.0 (1) 33.3 (9) 0.229
Cardiopathy % (n) 53.8 (7) 43.8 (14) 0.538
Previous stroke % (n) 30.8 (4) 15.6 (5) 0.411
rt-PA administration % (n) 84.6 (11) 43.8 (14) 0.012
Time-to-treatment, min mean 	 S.D. 166.33 	 63.83 144.15 	 61.81 0.424
TOAST 0.224
- Atherothrombotic % (n) 38.5 (5) 15.6 (5)
- Cardioembolic % (n) 53.8 (7) 53.1 (17)
- Undetermined % (n) 7.7 (1) 25.0 (8)
HT % (n) 28.6 (2) 16.7 (3) 0.597
In-hospital death % (n) 7.7 (1) 18.8 (6) 0.654
Z-SRSF1 median (IQR) 1.59 (1.59–1.59) 1.59 (1.59–2.14) 0.353
SAHH2 pg/ml median (IQR) 968.89 (886.43–1561.18) 1498.91 (1134.75–2305.35) 0.031
SAHH2  993.23 pg/ml % (n) 58.3 (7) 10.7 (3) 0.003
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expression in experimental models of ischemia (48–50). How-
ever, it is noteworthy that these results may vary between
species (51) and, currently, very little data exists on the ex-
pression of EAA2 in human brain in the context of ischemia.
Moreover, EAA2 expression might also vary depending on the
brain matter assessed, as Yatomi et al. showed an increase of
EAA2 in white matter regions of human brains after an ische-
mic event (52).
GABT is a mitochondrial enzyme responsible for the catab-
olism of gamma-aminobutyric acid (GABA), an important in-
hibitory neurotransmitter in the central nervous system, into
succinic semialdehyde. After an ischemic insult, there is a
substantial acute increase in extracellular concentration of
GABA in the brain. This minimizes the effect of extracellular
glutamate, with the concomitant decrease of GABA synthesis
probably because of an increase in glutamatergic activity (53).
As an increase in GABAergic activity decreases glutamatergic
activity, several therapeutic approaches have been designed
that aim to increase GABA’s function after acute ischemia.
These approaches have included the inhibition of GABT via
the GABA transaminase inhibitor vigabitrin, which has shown
a neuroprotective effect (53). In concordance with our results,
GABT was found to increase in gerbil brain hippocampus after
brain ischemia (54). In the human brain, GABT has previously
been reported to appear irregular and granular in many types
of neurons and glial cells in Alzheimer’s patients (55).
The protein expression changes of SRSF1 and SAHH2 in
regions affected by ischemia were completely verified in our
immunofluorescence assays. SRSF1 (also known as SF2/
ASF) is a serine/arginine rich protein with an important in-
volvement in post-transcriptional gene regulation (56). It par-
ticipates in both constitutive and alternative splicing, RNA
metabolism, RNA transport and translation (57). The action of
SRSF1 is essential for the regulation of angiogenesis and
vascular senescence as it is involved in the generation of
several vascular endothelial growth factor (VEGF) isoforms
(58) and tissue factor or endoglin (59). It has been also de-
scribed that SRSF1 overexpression activates the mTOR1 sig-
naling pathway, which plays a significant role in cellular
growth and protein translation (59). Thus, our results, showing
an enhanced expression of SRSF1 in the neurons of the IC
region, might reflect the implication of SRSF1 in processes
involved in tissue repair after ischemia. Interestingly, we also
detected a clear translocation of SRSF1 from the neuronal
nucleus to the cytoplasm after ischemia, which plausibly af-
fects its function within the cell for all its pleiotropic possibil-
ities. This compartment redistribution of SRSF1 is coordi-
nated through phosphorylation by serine/arginine-rich protein
kinases (SRPKs) (60–62) whose expression and location have
also been found to be altered after brain ischemia (63).
The protein SAHH2 (also known as AHCYL1 or IRBIT),
highly expressed in the brain (64), plays an important role in
the coordinated inhibition of Ca2 ion transporters through
the inactivation of 1, 4, 5-triphosphate receptors (IP3R) and it
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is involved in neurite cone extension (65). To the best of our
knowledge, SAHH2 has not been previously explored in the
context of stroke. Our results show an increased expression
of SAHH2 in neurons from the IC area probably because of
ischemia-triggered Ca2 mobilization.
Finally, we have explored the role of these 2 validated
candidates as blood biomarkers to differentiate ischemic
strokes from other neurological conditions and to assess
stroke prognosis. Neither of them improves stroke discrimi-
nation, however, their biological functions associated with
repair processes, suggest that they might exert a role in
stroke prognosis estimation. Accurate and early stroke prog-
nosis is essential to better evaluate the risks and benefits of
stroke treatment and management and thus represents a
unique opportunity for clinical interventions aimed at improv-
ing stroke outcome. Furthermore, some of the proteins iden-
tified here exclusively in the BBB structures, might be inter-
esting candidates to be assessed as biomarkers to predict
hemorrhagic transformation, one of the most feared compli-
cations of rt-PA treatment in stroke patients and associated
with BBB breakdown (66). In this sense, as those BBB can-
didates could not be validated by immunofluorescence assay,
such analysis was not explored here but further investigation
is warranted.
In the assessed cohort, only SAHH2 appeared as a poten-
tially valuable indicator of early stroke prognosis, with low
circulating levels associated with neurological improvement.
We found increased levels of SAHH2 in the IC brain regions of
patients who finally died because of stroke and, in relation to
this, higher SAHH2 levels in the bloodstream of patients with
neurological deterioration. The association of SAHH2 with
more Ca2 mobilization and glutamate excitotoxicity might
explain the overexpression of neuronal SAHH2 in patients
with enlarged cerebral lesions, who are prone to suffer
poorer outcomes (67). The release of cell content after
neuronal death might be another plausible explanation, with
more protein released when large damage occurs, although
causality cannot be extrapolated here. Nonetheless, the
discrimination of stroke outcome with SAHH2 showed a
high sensitivity (89%) but with a moderate specificity (58%).
The combination of SAHH2 in a panel with other prognosis
biomarkers, such as cytokines (68, 69) or metalloprotei-
nases (70), might complement the evaluation of clinical
outcome after stroke.
Moreover, the potential of SRSF1 and SAHH2, as well as
other identified proteins through MS and/or bioinformatics
analyses, as therapeutic targets seems promising and future
studies might assess them to drive neuronal recovery thera-
pies after the ischemic insult.
Our study had some limitations that need to be taken into
account and should be addressed in future and larger studies.
Although the stringent candidate selection criteria coupled
with a verification step by immunohistofluorescence supports
our findings, the number of patients included in the study
is relatively small but ischemic stroke patients’ brain necrop-
sies are rarely achieved as they are not needed for diagnosis
neither family counseling purposes. This limited sample size
influenced also in the reliability of our MS statistical analysis
through the parametric paired test available in Progenesis
software, although similar lists of significant proteins were
achieved by nonparametric tests (supplemental Fig. S2). In
addition, even though LMD allows the isolation of specific cell
types, it is extremely difficult to isolate cells with complex
morphology such as astrocytes using this technique. There-
fore, we were not able to perform a proteomic characteriza-
tion of these major brain cell types, which are highly relevant
in brain ischemia. Finally, because of ischemia the appear-
ance of subclinical edema or blood extravasation into the
brain parenchyma can occur. Thus, we cannot discard the
presence of proteins from the bloodstream, especially in IC
regions.
Our work also has some strengths that should be high-
lighted. Although a different response to protein degradation
processes cannot be dismissed between healthy and in-
farcted tissue, we have tried to control the influence of these
processes in the best possible manner by using the nonaf-
fected contralateral side of the same brain as control tissue,
being both samples obtained under the same conditions. The
brain changes because of ischemia disclosed here were ob-
served in a nonacute phase but they seem robust as they
were found in brain samples obtained at a wide range of times
after symptom onset. Following the presented approach, we
identified and evaluated new proteins (SRSF1 and SAHH2) in
the context of brain ischemia.
In conclusion, we were able to describe changes in the
protein expression profile from specific cerebral cell popu-
lations after stroke using a label-free MS quantification ap-
proach. These results contribute to increasing knowledge
on the molecular mechanisms of ischemic stroke pathology.
Moreover, we highlighted SAHH2 as an interesting can-
didate to be further assessed as a stroke prognostic
biomarker.
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